Vivos Q1 revenue down 10.5% to $3.4M, operating expenses cut 22%; Medicare reimbursement approved for CARE devices

Vivos Therapeutics, Inc.

2024-Q1 EPS reported -$1.63 revenue$3,419,000

Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.
Operating expenses down 22% YoY ($1.6M reduction); operating loss reduced 24% YoY.
Cash $2.6M at March 31; Feb 2024 warrant exercise raised ~$4.0M from 980,393 shares.
April 2024: received Medicare reimbursement approval for CARE oral devices, enabling coverage for beneficiaries.
Management targets cash flow positive from operations by end of 2024 or Q1 2025, assuming revenue growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.

Period: first quarter ended March 31, 2024
Revenue: $3.4 million
Result: reported results

Exact text from the filing

Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019739

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.